Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

3.700 -0.030 (-0.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 37,565
Open 3.730
Bid (Size) 3.480 (1)
Ask (Size) 3.960 (1)
Prev. Close 3.730
Today's Range 3.670 - 3.840
52wk Range 2.420 - 11.50
Shares Outstanding 20,595,503
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
From Syros Pharmaceuticals
Via Business Wire

Performance

YTD
+4.52%
+4.52%
1 Month
+17.46%
+17.46%
3 Month
-6.09%
-6.09%
6 Month
-3.39%
-3.39%
1 Year
-58.98%
-58.98%

More News

Read More
Syros Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals's Earnings Outlook
Via Benzinga
Syros Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Syros Pharmaceuticals's Earnings Outlook
Via Benzinga
Analyst Expectations for Syros Pharmaceuticals's Future
Via Benzinga
Syros Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Syros to Present at JMP Securities 2023 Life Sciences Conference
From Syros Pharmaceuticals
Via Business Wire
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Tesla To Rally Around 15%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Participate in Upcoming Investor Conferences in March
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
From Syros Pharmaceuticals, Inc.
Via Business Wire
Syros Announces Clinical Updates and 2023 Strategic Priorities
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.